Teva still in pursuit of Mylan, raises guidance
This article was originally published in Scrip
Teva has announced a solid first quarter on the back of a strong performance from its US generics business and has modestly raised its 2015 EPS by $0.05 to $5.05-$5.35.
You may also be interested in...
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.
Better dialogue with companies, together with new regulations and ways of working, have helped Brazil’s medicines regulator set new records for registering pharmaceuticals.